Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Inclusion Criteria: * Histologically or cytologically documented B-cell non-Hodgkin's lymphoma \[NHL\] (diffuse mixed, diffuse or follicular large B-cell, immunoblastic), Burkitt or Burkitt-like lymphomas, and primary effusion lymphomas. * Seropositive for HIV by any approved test (prior documentation of HIV seropositivity is acceptable). * Failed or relapsed after at least 1 prior chemotherapy treatment (chemotx) regimen but could have had no more than 2 prior chemotx regimens with only one of them being an anthracycline-containing regimen. Prior treatment (tx) with rituximab allowed. * All stages of disease * Measurable or evaluable tumor * Greater than or equal to 18 years of age * Karnofsky performance status greater than 50% * Absolute granulocyte count (AGC) greater than 1.0; platelets greater than 75,000; hemoglobin (Hgb) greater than 8.0 (unless these parameters are abnormal secondary to lymphomatous involvement of marrow, or due to HIV-related thrombocytopenia). * Bilirubin less than 2.0 (unless elevated secondary to lymphomatous involvement of liver or biliary system or due to other HIV-related medications such as Crixivan). * Creatinine less than 2.5 or creatinine clearance greater than 60 ml/min * Multigated acquisition (MUGA) scan or 2D echocardiogram indicating left ventricular ejection fraction (LVEF) greater than or equal to 50% within 42 days prior to first dose of study drug. * Patients with central nervous system (CNS) involvement are eligible provided tha…